title: A novel approach to paraneoplastic intestinal pseudo-obstruction.
abstract: Paraneoplastic neurologic syndromes (PNS) are uncommon, affecting fewer than 1 in 10,000 patients with cancer. PNS, while rare, can cause significant morbidity and impose enormous socio-economic costs, besides severely affecting quality of life. PNS can involve any part of the nervous system and can present as limbic encephalitis, subacute cerebellar ataxias, opsoclonus-myoclonus, retinopathies, chronic intestinal pseudo-obstruction (CIPO), sensory neuronopathy, Lambert-Eaton myasthenic syndrome, stiff-person syndrome, and encephalomyelitis. The standard of care for CIPO includes the use of promotility and anti-secretory agents and the resection of the non-functioning gut segment; all of which can cause significant compromise in the quality of life. There is significant evidence that paraneoplastic neurologic syndromes are associated with antibodies directed against certain nerve antigens. We successfully treated a patient with CIPO in the setting of small cell lung cancer with a combination of rituximab and cyclophosphamide. The patient, who had failed to respond to prokinetic agents, anti-secretory therapy, and multiple resections, responded to the immunomodulatory therapy, with minimal residuals with PEG tube feeding and sustained ostomy output. The use of rituximab and cyclophosphamide should therefore be considered in patients with CIPO, especially if it can avoid complicated surgical procedures.
authors.affiliation: University at Buffalo, Buffalo, NY, USA. badariar@gmail.com
authors.forename: Ambuga
authors.initials: A
authors.lastname: Badari
authors.forename: Deborah
authors.initials: D
authors.lastname: Farolino
authors.forename: Eiad
authors.initials: E
authors.lastname: Nasser
authors.forename: Shahid
authors.initials: S
authors.lastname: Mehboob
authors.forename: David
authors.initials: D
authors.lastname: Crossland
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D007418:Intestinal Pseudo-Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D020364:Paraneoplastic Polyneuropathy / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D011788:Quality of Life; D000069283:Rituximab; D055752:Small Cell Lung Carcinoma / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide
references.citation: Blood. 2001 Aug 15;98(4):952-7
references.pmid: 11493438
references.citation: Neurology. 1998 Mar;50(3):652-7
references.pmid: 9521251
references.citation: J Pediatr Gastroenterol Nutr. 2008 Apr;46(4):457-60
references.pmid: 18367961
references.citation: Gut. 2005 Sep;54(9):1343-4
references.pmid: 16099803
references.citation: Orphanet J Rare Dis. 2007 May 04;2:22
references.pmid: 17480225
references.citation: Blood. 1995 Jan 15;85(2):351-8
references.pmid: 7811992
references.citation: World J Gastroenterol. 2008 May 21;14(19):2953-61
references.pmid: 18494042
references.citation: Am J Gastroenterol. 2001 Feb;96(2):373-9
references.pmid: 11232678
references.citation: J Neurooncol. 2009 Jul;93(3):421-3
references.pmid: 19139820
references.citation: Neurogastroenterol Motil. 2004 Oct;16(5):515-31
references.pmid: 15500508
references.citation: Aliment Pharmacol Ther. 2008 Jul;28(1):25-42
references.pmid: 18410560
references.citation: Immunity. 2004 May;20(5):517-27
references.pmid: 15142521
references.citation: Gastroenterology. 2003 Jul;125(1):70-9
references.pmid: 12851872
references.citation: Am J Gastroenterol. 2002 Jul;97(7):1828-33
references.pmid: 12135044
references.citation: Gastroenterology. 1991 Jan;100(1):137-42
references.pmid: 1845756
references.citation: Pediatr Blood Cancer. 2009 Mar;52(3):396-8
references.pmid: 18989884
references.citation: J Neurol. 2006 Jan;253(1):16-20
references.pmid: 16444604